Discloses the monthly exercise status of stock acquisition rights (70th and 71st). The number of shares to be delivered for the subject month was 2,830,000 shares; exercised rights numbered 28,300 cases, with exercised shares totaling approximately 5,600 shares equivalent. Unexercised rights at month-end amounted to 408,700 shares, compared with 437,000 shares at the end of the prior month. Exercise restrictions were complied with; the exercise ratio was 3.5%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4582-20261102-01.pdf","jir_short_summary":"Discloses the monthly exercise status of stock acquisition rights (70th and 71st). The number of shares to be delivered for the subject month was 2,830,000 shares; exercised rights numbered 28,300 cases, with exercised shares totaling approximately 5,600 shares equivalent. Unexercised rights at month-end amounted to 408,700 shares, compared with 437,000 shares at the end of the prior month. Exercise restrictions were complied with; the exercise ratio was 3.5%.","jir_summary":"### Overview of Monthly Exercise Status\nThis report discloses the monthly exercise status for October 2026 of the 70th and 71st stock acquisition rights issued by third-party allotment. The number of shares to be delivered in the subject month was 2,830,000 shares; the number of stock acquisition rights exercised was 28,300 cases, representing 5.9% of the total issued amount of 480,000 cases. The number of unexercised stock acquisition rights at month-end was 408,700 shares, compared with 437,000 shares at the end of the previous month. For the 71st rights, disclosure of monthly exercise status is omitted because they are awaiting start-of-exercise instructions.\n\n### Exercise Restrictions and Future Impact\nExercise restrictions have been applied based on listing rules. The number of shares to be delivered this time is 2,830,000 shares, the listed shares are 80,247,210 shares, and the exercise ratio subject to restriction is reported as 3.5%. Under the terms of the purchase agreement, exercise in excess of restrictions is exempted when the exercise price is equal to or greater than the closing price on the date of the resolution to issue. Future treatment of the stock acquisition rights and market impact will depend on the contractual terms with EVO FUND.","jir_financial_highlights":"Number of shares to be delivered in the subject month: 2,830,000 shares\nNumber of stock acquisition rights exercised during the subject month: 28,300 cases\nTotal number of issued stock acquisition rights: 480,000 cases","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #StockOptions","jir_key_figures":"Number of shares to be delivered in the subject month: 2,830,000 shares\nNumber of stock acquisition rights exercised during the subject month: 28,300 cases\nTotal number of issued stock acquisition rights: 480,000 cases","jir_meta_title":"SymBio Pharmaceuticals: Monthly Exercise Status of Third-Party Allotted Stock Acquisition Rights \u2013 October 2026","jir_meta_description":"Detailed monthly exercise status for SymBio Pharmaceuticals' 70th and 71st stock acquisition rights for October 2026: 2,830,000 shares to be delivered, 28,300 rights exercised, 408,700 unexercised shares, and the status of exercise restrictions.","jir_og_title":"Monthly Exercise Status of Stock Acquisition Rights Issued by Third-Party Allotment \u2013 October 2026","jir_og_description":"Discloses the October exercise status of stock acquisition rights: 2,830,000 shares to be delivered, 28,300 rights exercised, 408,700 unexercised shares, and explanations on the application of exercise restrictions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-140088","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n